First Biosimilar, Tyruko, Approved to Treat Multiple Sclerosis

FRIDAY, Aug. 25, 2023 -- The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news